Press time:2016-05-19From:CR Pharmaceutical [ Font:BigMediumSmall]
China Resources Pharmaceutical and the National Center for Nanoscience and Technology signed a Strategic Cooperation Agreement between the National Center for Nanoscience and Technology and China Resources Pharmaceutical Group in Beijing on May 16. They also established a "joint lab on the research of the druggability of nano-materials".
At the signing ceremony, the Chinese medicine R&D center under China Resources Pharmaceutical and the National Center for Nanoscience and Technology signed a cooperation development agreement on a new category I drug, the irinotecan hydrochloride nano-micelle injection project. The two parties will jointly conduct the pre-clinical research and will jointly apply for the approval of conducting clinical studies.
After the signing ceremony, the two sides jointly held a seminar on the analysis of the druggability of nano-materials and conversion technology. At the seminar, there were discussions on the research of the druggability of nano-micelle, nano analysis technology in pharmaceutical dressing, standardization of the quality control of nano medicines, research progress in liposome nano medicines, and targeting polypeptide molecules mechanism.
China Resources Pharmaceutical has long attached great importance to research and innovation, and will capitalize on the signing of the strategic cooperation agreement to form a long-term and comprehensive partnership with the National Center for Nanoscience and Technology in the key areas of the research on the druggability of nano medicines and conversion technology. It will take full advantage of the respective advantages, push forward with project cooperation and conversion applications, and dedicate itself to achieving major breakthroughs in the research of nano medicines and conversion.
